Home › Melanoma › Michigan › Ann Arbor
Studi clinici su Melanoma a Ann Arbor, MI
12 studi su Melanoma cercano partecipanti presso sedi a Ann Arbor e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · a 7 mi di distanza
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · a 7 mi di distanza
- e altri 4
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
In reclutamentoFase 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · a 7 mi di distanza
- e altri 5
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
In reclutamentoFase 3
- University of Michigan, Ann Arbor
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
In reclutamentoFase 2
- Local Institution - 0119, Ann Arbor
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
In reclutamentoFase 2
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- University of Michigan - Brighton Center for Specialty Care, Brighton · a 18 mi di distanza
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
In reclutamentoFase 1/2
- C S Mott Children's Hospital, Ann Arbor
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- C S Mott Children's Hospital, Ann Arbor
Neoadjuvant Darovasertib in Primary Uveal Melanoma
In reclutamentoFase 3
- W Kellogg Eye Center, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Ann Arbor
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
In reclutamento
- University of Michigan, Ann Arbor
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
In reclutamento
- University of Michigan Medical Center, Ann Arbor
- University of Michigan - Brighton Center for Specialty Care, Brighton · a 18 mi di distanza
Studi su Melanoma in altre città
- Houston, TX59 studi
- New York City, NY38 studi
- Los Angeles, CA34 studi
- Nashville, TN33 studi
- Pittsburgh, PA31 studi
- Boston, MA26 studi
- Philadelphia, PA23 studi
- San Francisco, CA22 studi
- Atlanta, GA21 studi
- Durham, NC21 studi
- St. Louis, MO21 studi
- Columbus, OH21 studi
Altri studi a Ann Arbor
- Cancro alla prostata27 studi
- Cancro al seno26 studi
- Cancro del polmone non a piccole cellule26 studi
- Cancro (tutti i tipi)25 studi
- Cancro colorettale23 studi
- Cancro ai polmoni23 studi
- Insufficienza cardiaca22 studi
- Leucemia mieloide acuta17 studi
- Malattie cardiovascolari16 studi
- Cancro pancreatico14 studi
- Cancro al rene (carcinoma a cellule renali)12 studi
- Carcinoma a cellule squamose della testa e del collo12 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.